Inspire drops failed CF drug to focus on eye care & cuts 27% of work force
This article was originally published in Scrip
Executive Summary
Inspire Pharmaceuticals is dropping its failed cystic fibrosis drug candidate denufosol tetrasodium and cutting 65 positions, or 27% of its total staff, as it shifts its focus back to its eye care business.